IgG4-related disease is characterized by tumefactive infiltration of IgG4-bearing plasmablasts and other lymphocytes, along with ____ fibrosis, into one or multiple organs, with resultant organ enlargement, fibrosis, and dysfunction.

IgG4-related disease is characterized by tumefactive infiltration of IgG4-bearing plasmablasts and other lymphocytes, along with storiform fibrosis, into one or multiple organs, producing organ enlargement, fibrosis, and dysfunction.

B.6 Ch.13

Serum levels of IgG4 antibodies are elevated in approximately ____% of IgG4-RD cases.

Serum levels of IgG4 antibodies are elevated in approximately 80% of IgG4-RD cases.

B.6 Ch.13

Approximately ____% of patients with IgG4-RD have normal serum IgG4 concentrations despite classic histopathology, so a normal level does not exclude the disease.

Approximately 30% of patients have normal serum IgG4 concentrations despite classic histopathologic and immunohistochemical findings; such patients tend to have fewer affected organs.

Harrison's 22e Ch.380

The hallmark histopathology of IgG4-RD is a dense lymphoplasmacytic infiltrate, storiform fibrosis, and ____ (occlusion/inflammation of veins), with mild-to-moderate eosinophilia.

The hallmark pathology of IgG4-RD (consistent across organs) is a dense lymphoplasmacytic infiltrate, storiform fibrosis, and obliterative phlebitis, with mild-to-moderate eosinophilia.

Harrison's 22e Ch.380

Histologic features that argue AGAINST IgG4-RD include intense neutrophilic infiltration, leukocytoclasis, ____ inflammation, multinucleated giant cells, and fibrinoid necrosis.

Histologic features uncommon in IgG4-RD that mitigate against the diagnosis include intense neutrophilic infiltration, leukocytoclasis, granulomatous inflammation, multinucleated giant cells, and fibrinoid necrosis.

Harrison's 22e Ch.380

The typical IgG4-RD patient is a middle-aged to elderly ____; the male-to-female ratio is approximately ____:1.

The typical IgG4-RD patient is a middle-aged to elderly man; the male-to-female ratio is approximately 2:1, contrasting with most classic autoimmune diseases.

Harrison's 22e Ch.380

The 2019 ACR/EULAR IgG4-RD classification criteria require a total of ≥____ points, with entry requiring involvement of at least 1 of ____ specified organs.

The 2019 ACR/EULAR IgG4-RD classification criteria use a 3-step process (entry: ≥1 of 11 organs; 32 exclusion criteria; 8 weighted inclusion domains); a total of ≥20 points classifies IgG4-RD, with specificity ~98-99% and sensitivity ~82-86%.

Wallace, Ann Rheum Dis 2020;79(1):77-87

First-line therapy for IgG4-RD is ____, typically begun as prednisone ____ mg/day and then tapered.

Glucocorticoids are first-line therapy for IgG4-RD, generally begun as prednisone 40 mg/day and tapered toward discontinuation or a 5 mg/day maintenance dose; response is swift but steroid-free remissions are uncommon.

Harrison's 22e Ch.380; B.6 Ch.13

For relapsing or glucocorticoid-resistant IgG4-RD, B-cell depletion with ____ (anti-CD20) is an excellent second-line therapy, commonly dosed as two ____-g IV infusions ~15 days apart.

For relapsing or glucocorticoid-resistant IgG4-RD, B-cell depletion with rituximab (anti-CD20) is an excellent second-line therapy, commonly dosed as two 1-g IV infusions separated by ~15 days.

Harrison's 22e Ch.380; B.6 Ch.13

In the MITIGATE phase 3 trial, the anti-CD19 antibody inebilizumab reduced the risk of IgG4-RD flare by ____%, and in April 2025 became the ____ FDA-approved therapy for IgG4-RD.

In the phase 3 MITIGATE trial, the anti-CD19 antibody inebilizumab reduced the risk of IgG4-RD flare by 87% (HR 0.13); in April 2025 it became the first FDA-approved therapy for IgG4-RD.

Stone, N Engl J Med 2025;392:1168-1177; Amgen, April 2025

Obexelimab is a bifunctional antibody that co-engages CD19 and the inhibitory ____ receptor to suppress B cells WITHOUT depleting them; in the INDIGO trial it reduced first flare by ____%.

Obexelimab is a bifunctional antibody that co-engages CD19 and the inhibitory FcγRIIb receptor to suppress B cells WITHOUT depleting them; in the phase 3 INDIGO trial it reduced first flare by 56% (HR 0.44).

Della-Torre, N Engl J Med 2026 (INDIGO)

____ disease — enlargement of the lacrimal, parotid, and submandibular glands — was once considered a subset of ____ syndrome but is now recognized as a common presentation of IgG4-RD.

Mikulicz disease — enlargement of the lacrimal, parotid, and submandibular glands — was once considered a subset of Sjögren syndrome but is now recognized as one of the most common presentations of IgG4-RD.

Harrison's 22e Ch.380; B.6 Ch.13

The paradigm of IgG4-RD is type 1 (IgG4-related) autoimmune ____; imaging shows a diffusely enlarged '____-shaped' pancreas, mimicking adenocarcinoma.

The paradigm of IgG4-RD is type 1 (IgG4-related) autoimmune pancreatitis, presenting with a diffusely enlarged 'sausage-shaped' pancreas and obstructive jaundice that mimics pancreatic adenocarcinoma.

Harrison's 22e Ch.380

Tap a card to flip it.